BioSpace News Archive

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for OFEV (nintedanib), investigating a potential treatment for children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease (ILD).

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced that it has installed its 100th MERSCOPE instrument in the Single Cell Genomics Core at the Baylor College of Medicine Department of Molecular and Human Genetics led by Dr. Rui Chen.

Hoth Therapeutics, Inc. today announced today that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value diagnostic and therapeutic solutions to improve ocular disease, proudly announces the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers.

Rhinostics introduces another breakthrough in automated sample collection technologies with the launch of the patent-pending ELEstic™ swab collection device combined with the groundbreaking ELEbot™ Decapper.

Gemina Laboratories Ltd. is excited to announce another major innovation in lateral flow assay test design resulting from its innovative, patented Gemina Bridge chemistry platform.

DNAnexus Inc. today announced that Fore Genomics, a proactive genetic testing company designed for healthy newborns, infants, and children, is using the DNAnexus platform for its FORESITE 360 test.

bluebird bio, Inc. (Nasdaq: BLUE) today announced it will hold a conference call to discuss second quarter 2023 financial results and provide a commercial update on Tuesday, August 8 at 8:00 a.m. ET. In addition to providing an overview of the business, the conference call will highlight the Company’s ongoing commercial launches of SKYSONA ® and ZYNTEGLO ® and the market opportunity for lovo-cel.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, has installed the first SRT-100™ System in Ireland at Dublin’s Beacon Hospital.

Combined Therapeutics, Inc. today announced the participation of Dr. Romain Micol, President and CEO of Combined Therapeutics, as a featured speaker at the 3rd mRNA-Based Therapeutics Summit.